JP2001507212A5 - - Google Patents

Download PDF

Info

Publication number
JP2001507212A5
JP2001507212A5 JP1998516567A JP51656798A JP2001507212A5 JP 2001507212 A5 JP2001507212 A5 JP 2001507212A5 JP 1998516567 A JP1998516567 A JP 1998516567A JP 51656798 A JP51656798 A JP 51656798A JP 2001507212 A5 JP2001507212 A5 JP 2001507212A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998516567A
Other languages
English (en)
Japanese (ja)
Other versions
JP3799483B2 (ja
JP2001507212A (ja
Filing date
Publication date
Priority claimed from US08/725,182 external-priority patent/US5804381A/en
Application filed filed Critical
Publication of JP2001507212A publication Critical patent/JP2001507212A/ja
Publication of JP2001507212A5 publication Critical patent/JP2001507212A5/ja
Application granted granted Critical
Publication of JP3799483B2 publication Critical patent/JP3799483B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP51656798A 1996-10-03 1997-09-15 ガン関連抗原をコードする単離核酸分子、その抗原、およびそれらの利用方法 Expired - Lifetime JP3799483B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/725,182 1996-10-03
US08/725,182 US5804381A (en) 1996-10-03 1996-10-03 Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof
PCT/US1997/016335 WO1998014464A1 (en) 1996-10-03 1997-09-15 Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof

Publications (3)

Publication Number Publication Date
JP2001507212A JP2001507212A (ja) 2001-06-05
JP2001507212A5 true JP2001507212A5 (https=) 2004-10-14
JP3799483B2 JP3799483B2 (ja) 2006-07-19

Family

ID=24913488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51656798A Expired - Lifetime JP3799483B2 (ja) 1996-10-03 1997-09-15 ガン関連抗原をコードする単離核酸分子、その抗原、およびそれらの利用方法

Country Status (14)

Country Link
US (2) US5804381A (https=)
EP (1) EP0948518B1 (https=)
JP (1) JP3799483B2 (https=)
KR (1) KR20000048851A (https=)
CN (1) CN1283652C (https=)
AT (1) ATE260930T1 (https=)
AU (1) AU732068B2 (https=)
CA (1) CA2266319C (https=)
DE (1) DE69727966T2 (https=)
DK (1) DK0948518T3 (https=)
ES (1) ES2216169T3 (https=)
NZ (1) NZ335485A (https=)
PT (1) PT948518E (https=)
WO (1) WO1998014464A1 (https=)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US6417165B1 (en) 1988-03-27 2002-07-09 Ludwig Institute For Cancer Research NY-ESO-1-peptide derivatives, and uses thereof
US6252052B1 (en) * 1996-10-03 2001-06-26 Cornell Research Foundation, Inc Antibodies which bind to NY-ESO-1 cancer associated proteins, and hybridomas which produce these antibodies
US6255470B1 (en) * 1996-10-03 2001-07-03 Memorial Sloan-Kettering Cancer Center Isolated nucleic acid molecule encoding an esophageal cancer associated antigen
US6251603B1 (en) * 1996-10-03 2001-06-26 Ludwig Institute For Cancer Research Method for determining status of a cancerous condition by determining antibodies to NY-ESO-1 in a patient sample
US7888100B2 (en) * 1996-10-03 2011-02-15 Memorial Sloan-Kettering Cancer Research Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein
PT970206E (pt) 1997-01-27 2008-10-28 Ludwig Inst Cancer Res Ácidos nucleicos lage-1 associados a tumores
US6794131B1 (en) 1998-01-27 2004-09-21 Ludwig Institute For Cancer Research Lage-1 tumor associated nucleic acids
US6673350B2 (en) * 1997-05-05 2004-01-06 Ludwig Institute For Cancer Research Tumor associated peptide and uses thereof
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
EP1806403A3 (en) * 1997-10-08 2008-01-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Human cancer antigen NY ESO 1/CAG-3 and gene encoding same
AU9572098A (en) * 1997-10-08 1999-04-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel human cancer antigen ny eso-1/cag-3 and gene encoding same
US7084239B1 (en) 1997-10-08 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cancer peptides of NY-ESO-1/CAG-3
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
AU3246200A (en) * 1999-02-25 2000-09-14 Boris Bilynsky Nucleic acid molecules associated with melanoma and thyroid tumors
DE19949595A1 (de) 1999-10-14 2001-05-03 Deutsches Krebsforsch CTAGE-Genfamilie
ATE395930T1 (de) 1999-10-22 2008-06-15 Aventis Pasteur Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
US6689742B1 (en) * 2000-02-25 2004-02-10 Chancellors, Masters And Scholars Of The University Of Oxford NY-ESO-1 peptide derivatives, and uses thereof
AU2001250828A1 (en) * 2000-03-14 2001-09-24 The Johns Hopkins University School Of Medicine Immunogenic ovarian cancer genes
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
EP1752160A3 (en) 2001-04-06 2007-05-30 Mannkind Corporation Epitope sequences
WO2002086071A2 (en) * 2001-04-20 2002-10-31 Ludwig Institute For Cancer Research Cancer-testis antigens
US7803382B2 (en) * 2001-05-04 2010-09-28 Ludwig Institute For Cancer Research Ltd. Method for inducing immune response to NY-CO-58
US6794501B2 (en) * 2001-05-04 2004-09-21 Ludwig Institute For Cancer Research Colon cancer antigen panel
US8637305B2 (en) 2001-11-07 2014-01-28 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
CN1646160A (zh) * 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
WO2004022709A2 (en) * 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
WO2005000870A2 (en) * 2003-05-30 2005-01-06 Ludwig Institute Of Cancer Research Isolated ny-eso-1 peptides which bind to hla class ii molecules and uses thereof
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
AU2004249254B2 (en) 2003-06-17 2010-07-08 Mannkind Corporation Combinations of tumor-associated antigens for the treatment of various types of cancers
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
WO2005114203A2 (en) * 2004-05-20 2005-12-01 The Regents Of The University Of California Dominant b cell epitopes and methods of making and using thereof
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US8202841B2 (en) 2004-06-17 2012-06-19 Mannkind Corporation SSX-2 peptide analogs
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
US20060165711A1 (en) * 2004-12-29 2006-07-27 Bot Adrian I Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
CN101687020A (zh) 2005-06-17 2010-03-31 曼康公司 用于癌症的多价引发-和-增强免疫治疗剂
MX2007015933A (es) 2005-06-17 2008-04-21 Mannkind Corp Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
NZ564359A (en) * 2005-06-17 2011-09-30 Mannkind Corp Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
NZ599777A (en) 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
AU2009223727B2 (en) 2008-03-14 2014-09-11 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
CA2755734A1 (en) 2009-03-17 2010-09-23 Gaetan Otto Improved detection of gene expression
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
EP3165540A1 (en) 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antibodies that bind human cd27 and uses thereof
HRP20211595T1 (hr) 2011-05-24 2022-01-21 BioNTech SE Individualizirana cjepiva protiv raka
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US8490054B2 (en) 2011-09-23 2013-07-16 The United States Of America As Represented By The Secretary Of The Army Software and related software tracking during software modification
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014074785A1 (en) 2012-11-08 2014-05-15 Ludwig Institute For Cancer Research Ltd. Methods of predicting outcome and treating breast cancer
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
EP3194970B1 (en) 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
TN2019000101A1 (en) 2015-05-29 2020-07-15 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof.
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
NL2018803B1 (en) 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
KR20220113492A (ko) 2019-12-11 2022-08-12 몰리큘라 파트너스 아게 변경된 표면 잔기를 갖는 설계된 안키린 반복 도메인

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772547A (en) * 1986-02-03 1988-09-20 Hoffmann-La Roche Inc. HTLV-III envelope peptides
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5212085A (en) 1987-12-09 1993-05-18 The General Hospital Corporation Sf-25 colon adenocarcinoma antigen, and antibodies with recognize this antigen
US5858689A (en) * 1993-07-22 1999-01-12 Ludwig Institute For Cancer Research Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5830753A (en) * 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
AU9572098A (en) 1997-10-08 1999-04-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel human cancer antigen ny eso-1/cag-3 and gene encoding same

Similar Documents

Publication Publication Date Title
JP2000508702A5 (https=)
JP2000508686A5 (https=)
JP2000505621A5 (https=)
JP2000511060A5 (https=)
JP2002504276A5 (https=)
JP2000509745A5 (https=)
JP2000507594A5 (https=)
JP2001517381A5 (https=)
JP2000511380A5 (https=)
JP2001502652A5 (https=)
JP2000503853A5 (https=)
JP2001507212A5 (https=)
JP2000511806A5 (https=)
JP2000504327A5 (https=)
JP2000510060A5 (https=)
JP2000509620A5 (https=)
JP2000506482A5 (https=)
JP2000511249A5 (https=)
JP2000507155A5 (https=)
JP2000506853A5 (https=)
JP2000510848A5 (https=)
JP2000508668A5 (https=)
JP2000505830A5 (https=)
JP2000505916A5 (https=)
JP2000506168A5 (https=)